Atria Investments Inc Sells 991 Shares of Haemonetics Co. (NYSE:HAE)

Atria Investments Inc decreased its position in shares of Haemonetics Co. (NYSE:HAE) by 23.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,221 shares of the medical instruments supplier’s stock after selling 991 shares during the quarter. Atria Investments Inc’s holdings in Haemonetics were worth $259,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Haemonetics during the second quarter worth approximately $39,000. Daiwa Securities Group Inc. bought a new position in Haemonetics during the second quarter worth about $82,000. Canada Pension Plan Investment Board acquired a new position in shares of Haemonetics during the 2nd quarter worth about $83,000. Nisa Investment Advisors LLC grew its position in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 632 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Haemonetics in the 2nd quarter valued at about $140,000. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on HAE shares. JMP Securities reissued a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Citigroup decreased their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. BTIG Research began coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. Barrington Research reiterated an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a report on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a report on Friday, November 15th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Price Performance

Shares of NYSE HAE opened at $85.55 on Friday. The company has a fifty day moving average price of $78.75 and a 200 day moving average price of $82.40. The firm has a market cap of $4.30 billion, a PE ratio of 35.50, a PEG ratio of 1.33 and a beta of 0.32. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.99 earnings per share. Research analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.